Up-regulation of ST18 in pemphigus vulgaris drives a self-amplifying p53-dependent pathomechanism resulting in decreased desmoglein 3 expression.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 04 2022
Historique:
received: 24 11 2021
accepted: 14 03 2022
entrez: 9 4 2022
pubmed: 10 4 2022
medline: 13 4 2022
Statut: epublish

Résumé

Pemphigus vulgaris (PV) is a life-threatening autoimmune mucocutaneous blistering disease which is to a large extent genetically determined, and results, at least in part, from the deleterious activity of autoantibodies directed against desmoglein (DSG)3, a prominent intra-epidermal adhesion molecule. Those autoantibodies lead to decreased membranal DSG3 expression in keratinocytes (KCs), thereby destabilizing cell-cell adhesion within the epidermis and leading to blister formation. We previously showed that rs17315309, a strong risk variant for PV within the promoter of the ST18 transcription factor gene, promotes epidermal ST18 up-regulation in a p53/p63-dependent manner. Accordingly, ST18 was found to be overexpressed in the skin of PV patients. Increased ST18 expression was then shown to markedly augment PV autoantibodies-mediated loss of KCs cohesion. Here, we demonstrate that ST18 overexpression significantly increases autoantibody-mediated DSG3 down-regulation in keratinocytes. In addition, DSG3 decreased expression boosts p53 function through p38 mitogen-activated protein kinase (p38MAPK) activation and dramatically augments p53-dependent ST18 promoter activity. Finally, the PV risk variant rs17315309 is associated with increased p53 expression in PV skin. Taken collectively, these observations reveal a novel self-amplifying pathomechanism involving ST18, DSG3, p38 and p53, capable of perpetuating disease activity, and therefore indicative of novel actionable molecular targets in PV.

Identifiants

pubmed: 35396567
doi: 10.1038/s41598-022-09951-x
pii: 10.1038/s41598-022-09951-x
pmc: PMC8993920
doi:

Substances chimiques

Autoantibodies 0
DSG3 protein, human 0
Desmoglein 3 0
Repressor Proteins 0
ST18 protein, human 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
p38 Mitogen-Activated Protein Kinases EC 2.7.11.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5958

Informations de copyright

© 2022. The Author(s).

Références

Front Immunol. 2019 Oct 15;10:2327
pubmed: 31749790
Dermatol Clin. 2011 Jul;29(3):373-80, vii
pubmed: 21605802
Exp Dermatol. 2018 Dec;27(12):1395-1398
pubmed: 30192416
Front Med (Lausanne). 2021 Aug 09;8:701809
pubmed: 34434944
Blood. 2015 Sep 17;126(12):1473-82
pubmed: 26228485
J Invest Dermatol. 2005 May;124(5):939-46
pubmed: 15854034
Immunol Res. 2018 Apr;66(2):255-270
pubmed: 29479654
Front Immunol. 2019 Apr 17;10:770
pubmed: 31057535
J Biol Chem. 2005 Jun 24;280(25):23778-84
pubmed: 15840580
Front Immunol. 2018 Mar 19;9:528
pubmed: 29616033
JID Innov. 2021 Feb 20;1(1):100004
pubmed: 34909708
Front Med (Lausanne). 2018 Aug 14;5:226
pubmed: 30155467
J Biol Chem. 2019 Mar 22;294(12):4520-4528
pubmed: 30692201
J Immunol. 2003 Feb 15;170(4):2170-8
pubmed: 12574390
J Clin Invest. 2015 Jun;125(6):2228-33
pubmed: 25893595
PLoS Genet. 2016 May 05;12(5):e1006008
pubmed: 27148741
Genet Med. 2020 Jul;22(7):1227-1234
pubmed: 32336749
Clin Rev Allergy Immunol. 2018 Feb;54(1):1-25
pubmed: 29313220
J Invest Dermatol. 2018 Jan;138(1):32-37
pubmed: 29037765
J Invest Dermatol. 2016 Jan;136(1):301-10
pubmed: 26763450
Genet Mol Biol. 2020;43(3):e20190369
pubmed: 32639508
J Dermatol. 2014 Apr;41(4):353-4
pubmed: 24612320
J Allergy Clin Immunol. 2020 Apr;145(4):1031-1047
pubmed: 32272980
Cancer Res. 2000 May 1;60(9):2464-72
pubmed: 10811125
FASEB J. 2008 Nov;22(11):3956-67
pubmed: 18676404
Am J Physiol Lung Cell Mol Physiol. 2015 Apr 15;308(8):L776-87
pubmed: 25713322
Cell Death Dis. 2019 Oct 3;10(10):750
pubmed: 31582719
Br J Dermatol. 2021 Jun;184(6):1153-1160
pubmed: 33205400
Biochim Biophys Acta. 2013 Aug;1830(8):4053-64
pubmed: 23583370
J Invest Dermatol. 2012 Jul;132(7):1798-805
pubmed: 22437316
Lancet. 2019 Sep 7;394(10201):882-894
pubmed: 31498102
Exp Dermatol. 2016 Nov;25(11):839-846
pubmed: 27305362
Science. 1991 Jun 21;252(5013):1708-11
pubmed: 2047879
Br J Dermatol. 2017 Dec;177(6):1612-1618
pubmed: 28600798
Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12855-60
pubmed: 16908851

Auteurs

Sari Assaf (S)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dan Vodo (D)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.

Kiril Malovitski (K)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Janan Mohamad (J)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shir Bergson (S)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Yarden Feller (Y)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Liron Malki (L)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ofer Sarig (O)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel.

Eli Sprecher (E)

Division of Dermatology, Tel Aviv Sourasky Medical Center, 6, Weizmann street, 64239, Tel Aviv, Israel. elisp@tlvmc.gov.il.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. elisp@tlvmc.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH